$2.40
0.07[3.00%]
Last update: 9:28AM Get Real Time Here
Alterity Therapeutics
(NASDAQ:ATHE)Alterity Therapeutics Stock (NASDAQ:ATHE), Analyst Ratings, Price Targets, Predictions
Alterity Therapeutics Ltd has a consensus price target of $5.25, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Ladenburg Thalmann, and Ladenburg Thalmann on March 7, 2024, June 5, 2023, and August 3, 2022. With an average price target of $5.33 between Benchmark, Ladenburg Thalmann, and Ladenburg Thalmann, there's an implied 131.87% upside for Alterity Therapeutics Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Ladenburg Thalmann
Goldman Sachs
Benchmark
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Alterity Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/07/2024 | ATHE | Buy Now | Alterity Therapeutics | $2.30 | 73.91% | Benchmark | Robert Wasserman | → $4 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 06/05/2023 | ATHE | Buy Now | Alterity Therapeutics | $2.30 | 334.76% | Ladenburg Thalmann | Aydin Huseynov | $20 → $10 | Maintains | Buy | Get Alert |
| 08/03/2022 | ATHE | Buy Now | Alterity Therapeutics | $2.30 | -13.05% | Ladenburg Thalmann | Aydin Huseynov | → $20 | Initiates | → Buy | Get Alert |
| 06/23/2022 | ATHE | Buy Now | Alterity Therapeutics | $2.30 | 30.43% | Goldman Sachs | — | $110 → $30 | Maintains | Neutral | Get Alert |
| 08/20/2021 | ATHE | Buy Now | Alterity Therapeutics | $2.30 | 73.91% | Benchmark | Aydin Huseynov | — | Initiates | → Speculative Buy | Get Alert |
FAQ
What is the target price for Alterity Therapeutics (ATHE)?
The latest price target for Alterity Therapeutics (NASDAQ: ATHE) was reported by Benchmark on March 7, 2024. The analyst firm set a price target for $4.00 expecting ATHE to rise to within 12 months (a possible 66.67% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alterity Therapeutics (ATHE)?
The latest analyst rating for Alterity Therapeutics (NASDAQ: ATHE) was provided by Benchmark, and Alterity Therapeutics reiterated their speculative buy rating.
When was the last upgrade for Alterity Therapeutics (ATHE)?
There is no last upgrade for Alterity Therapeutics.
When was the last downgrade for Alterity Therapeutics (ATHE)?
There is no last downgrade for Alterity Therapeutics.
When is the next analyst rating going to be posted or updated for Alterity Therapeutics (ATHE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alterity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alterity Therapeutics was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
Is the Analyst Rating Alterity Therapeutics (ATHE) correct?
While ratings are subjective and will change, the latest Alterity Therapeutics (ATHE) rating was a reiterated with a price target of $0.00 to $4.00. The current price Alterity Therapeutics (ATHE) is trading at is $2.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.